Table 3.
Presence of factors predisposing to the development of candidemia in the study population
| Factor | Immunocompromised patients (n = 9) | Nonimmunocompromised patients (n = 15) | p value |
|---|---|---|---|
| Age in years, mean±SD | 50 ± 5.9 | 58 ± 9.6 | >0.05 |
| Apache II score, mean±SD | 24 ± 3 | 20 ± 3 | 0.04 |
| SOFA score, mean±SD | 8 ± 1 | 6 ± 2 | 0.04 |
| Broad-spectrum antibiotics, no. (%) | 9 (100) | 15 (100) | >0.05 |
| Central venous catheter, no. (%) | 9 (100) | 15 (100) | >0.05 |
| Total parenteral nutrition, no. (%) | 9 (100) | 8 (53) | 0.02 |
| CVVH, no. (%) | 4 (44) | 5 (33) | >0.05 |
| Diabetes mellitus, no. (%) | 1 (11) | 4 (27) | >0.05 |
| Systemic corticosteroids, no. (%) | 7 (47) | 6 (40) | >0.05 |
SOFA Sequestrial Organ Failure Assessment score, CVVH continuous venovenous hemofiltration